At a glance

Established by Integra Holdings and XL Vision Sciences, fully owned by BioLight Lifesciences Investments, in 2014, OPhRx is developing novel drug products for topical administration for diseases involving front-of the eye and back of the eye compartments. Developments will follow the 505(b)2 regulatory process based on the delivery platform invented by Prof. Nissim Garti from the Hebrew University.

Market Potential

In 2015, the global sales of the current ophthalmic products, for which improvements are attempted by OPhRx platform, exceeded $5 Billion.

Company Highlights

Novel, fully synthetic proprietary formulations for topical use in Ophthalmology are being developed based on the technology of Prof. Garti, former Head, Casali Institute of Applied Chemistry and a world leader in surfactants science. The drug delivery technology utilizes lyotropic liquid crystals, as an alternative to current formulation technologies. OphRx is currently in the preclinical stage of development of two product candidates: OPH-101, an alternative topical treatment to intravitreal injections for wet age related macular degeneration (AMD), and OPH-100, a treatment for Dry Eye Syndrome (DES).

Key Shareholders

Integra Holdings, XL-Vision Sciences, Yissum, Kremer & Lieberman groups.

Funding

Extensive business development activity will be initiated at completion of preclinical proof of concept.